Which of the following is NOT a side effect of GLP-1 agonists?

GLP-1 agonists, which are used primarily for the management of type 2 diabetes and sometimes for weight loss, are known to produce several effects on the body. Among these effects, weight loss, gastrointestinal symptoms, and potential associations with thyroid tumors are often noted.

Weight loss is a common and intended side effect of GLP-1 agonists, as these medications tend to suppress appetite and promote satiety, leading to reduced food intake. GI symptoms such as nausea, vomiting, and diarrhea are also frequently experienced by patients, particularly when starting the medication. Additionally, there is a concern regarding the potential link between GLP-1 agonists and thyroid tumors, which has been observed in rodent studies, leading to caution in prescribing these drugs, especially in individuals with a personal or family history of medullary thyroid carcinoma.

In contrast, increased appetite is not a characteristic side effect of GLP-1 agonists. These medications are specifically designed to counteract increased appetite and promote weight loss. Therefore, identifying increased appetite as an effect of GLP-1 agonists is incorrect, making it the right choice in the context of side effects not associated with these drugs.